Amphastar Pharmaceuticals (AMPH) Revenue (2013 - 2026)

Amphastar Pharmaceuticals' Revenue history runs 14 years deep, the most recent figure standing at $171.2 million for Q1 2026.

• On a quarterly basis, Revenue changed 0.38% year-over-year to $171.2 million in Q1 2026; TTM through Mar 2026 was $720.5 million, a 1.39% decrease from a year earlier, with the FY2025 full-year figure at $719.9 million, down 1.65% from the prior year.
• Revenue retreated to $171.2 million in Q1 2026 per AMPH's latest filing, from $183.1 million in the prior quarter.
• Across five years, Revenue topped out at $191.8 million in Q3 2025 and bottomed at $120.1 million in Q3 2022.
• The 5-year median for Revenue is $171.8 million (2024), against an average of $162.7 million.
• Across the five-year window, Revenue surged 50.3% in 2023 and dropped 4.38% in 2025, its largest moves.
• Year by year, Revenue stood at $135.0 million in 2022, then soared by 31.91% to $178.1 million in 2023, then increased by 4.73% to $186.5 million in 2024, then decreased by 1.83% to $183.1 million in 2025, then retreated by 6.52% to $171.2 million in 2026.
• Per Business Quant, the three latest AMPH Revenue figures stand at $171.2 million (Q1 2026), $183.1 million (Q4 2025), and $191.8 million (Q3 2025).